IMCR News and Press, Immunocore Holdings plc From 05/18/21

Immunocore Holdings (IMCR) announces the dosing of the first patient in the first-in-human clinical trial of IMC-I109V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with chronic hepatitis B ((HBV)) infection ((CHB)).The trial ...

PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV ® bispecific molecule for chronic Hepatitis B IMC-I109V studied for the treatment of non- cirrhotic HBeAg -negative chronic hepatitis B (HBV) i...

Immunocore (IMCR): Q1 net loss of $40.05M.Revenue of $11.4M beats by $1.22M.Press Release For further details see: Immunocore beats on revenue

PRESS RELEASE Immunocore Reports First Quarter 202 1 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration ( FDA ) is expected to be complet ed in third ...

PRESS RELEASE Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Overall survival benefit from tebentafusp in patients with best response of progressive disea...

Immunocore (IMCR) announces positive data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma ((mUM)) in the clinical trial plenary session at the American Association for Cancer Research ((AACR))...

PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to im...

Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...

Immunocore (IMCR): FY GAAP EPS of -$2.79 beats by $9.00.Revenue of $30.1M (+17.1% Y/Y) misses by $7.44M.Press Release For further details see: Immunocore EPS beats by $9.00, misses on revenue

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal melanoma Tebentafusp Phase 3 randomized trial data subject of an o...